Müller, Sebastian Johannes
Khadhraoui, Eya
Hansen, Niels
Jamous, Ala
Langer, Philip
Wiltfang, Jens
Riedel, Christian Heiner
Bouter, Caroline
van Riesen, Christoph
Maass, Fabian
Bartl, Michael
Lange, Claudia
Ernst, Marielle
Funding for this research was provided by:
Georg-August-Universität Göttingen
Article History
Received: 21 December 2022
Accepted: 8 March 2023
First Online: 21 March 2023
Declarations
:
: This study was ethically approved by the institutional review board of the University Medical Center Göttingen (No. 16/04/2022, “Ethics Committee of the University of Göttingen”, Von-Siebold-Str. 4, 37075 Göttingen, Germany) and adhered to the 2013 Helsinki Declaration.Due to the retrospective, observational nature of the study, the ethics committee (“Ethics Committee of the University of Göttingen”) waived the need for informed consent.
: Not applicable.
: The authors declare that they have no competing interests. JW is an advisory board member of Abbott, Biogen, Boehringer Ingelheim, Immunogenetics, Lilly, MSD Sharp & Dohme, and Roche Pharma. JW received honoraria for lectures from the AGNP, Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., CSF-Society, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and Vitos Kurhessen-Bad Emstal. JW holds the following patents: PCT/EP 2011 001724 and PCT/EP 2015 052945, MB has received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 413501650. FM received speaker honoraria from BIAL and Abbvie. CvR speaker honoraria/counseling for Abbvie and Zambon.